Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 31.71 Million EUR | -38.63% |
| 2022 | 51.67 Million EUR | -13.1% |
| 2021 | 59.47 Million EUR | -20.44% |
| 2020 | 74.75 Million EUR | -31.56% |
| 2019 | 109.21 Million EUR | -12.57% |
| 2018 | 124.91 Million EUR | 11.59% |
| 2017 | 111.93 Million EUR | 0.2% |
| 2016 | 111.71 Million EUR | -1.6% |
| 2015 | 113.53 Million EUR | 59.27% |
| 2014 | 71.28 Million EUR | 35.38% |
| 2013 | 52.65 Million EUR | -14.04% |
| 2012 | 61.25 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 28.81 Million EUR | 0.0% |
| 2023 Q4 | 31.71 Million EUR | 0.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 42.17 Million EUR | 0.0% |
| 2023 Q3 | 31.71 Million EUR | -24.8% |
| 2023 FY | 31.71 Million EUR | -38.63% |
| 2022 Q2 | 76.49 Million EUR | 0.0% |
| 2022 FY | 51.67 Million EUR | -13.1% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 51.67 Million EUR | 0.0% |
| 2022 Q3 | 51.67 Million EUR | -32.45% |
| 2021 Q4 | 59.47 Million EUR | 0.0% |
| 2021 Q3 | 59.47 Million EUR | -11.07% |
| 2021 FY | 59.47 Million EUR | -20.44% |
| 2021 Q2 | 66.87 Million EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2020 FY | 74.75 Million EUR | -31.56% |
| 2020 Q2 | 93.1 Million EUR | 0.0% |
| 2020 Q3 | 74.75 Million EUR | -19.71% |
| 2020 Q4 | 74.75 Million EUR | 0.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q3 | 117.38 Million EUR | -3.47% |
| 2019 Q1 | 128.21 Million EUR | 2.65% |
| 2019 Q2 | 121.6 Million EUR | -5.16% |
| 2019 FY | 109.21 Million EUR | -12.57% |
| 2019 Q4 | 109.21 Million EUR | -6.96% |
| 2018 Q2 | 138.63 Million EUR | 28.53% |
| 2018 FY | 124.91 Million EUR | 11.59% |
| 2018 Q4 | 124.91 Million EUR | -6.77% |
| 2018 Q3 | 133.99 Million EUR | -3.35% |
| 2018 Q1 | 107.86 Million EUR | -3.64% |
| 2017 Q2 | 119.82 Million EUR | 13.21% |
| 2017 Q1 | 105.83 Million EUR | -5.26% |
| 2017 FY | 111.93 Million EUR | 0.2% |
| 2017 Q4 | 111.93 Million EUR | -2.56% |
| 2017 Q3 | 114.87 Million EUR | -4.13% |
| 2016 FY | 111.71 Million EUR | -1.6% |
| 2016 Q2 | 105.59 Million EUR | -4.08% |
| 2016 Q4 | 111.71 Million EUR | -3.0% |
| 2016 Q1 | 110.09 Million EUR | -3.03% |
| 2016 Q3 | 115.17 Million EUR | 9.07% |
| 2015 Q4 | 113.53 Million EUR | -1.9% |
| 2015 Q1 | 69.72 Million EUR | -2.18% |
| 2015 Q3 | 115.73 Million EUR | 55.02% |
| 2015 Q2 | 74.65 Million EUR | 7.07% |
| 2015 FY | 113.53 Million EUR | 59.27% |
| 2014 Q2 | 57.17 Million EUR | -2.68% |
| 2014 FY | 71.28 Million EUR | 35.38% |
| 2014 Q4 | 71.28 Million EUR | 3.01% |
| 2014 Q3 | 69.2 Million EUR | 21.04% |
| 2014 Q1 | 58.74 Million EUR | 11.57% |
| 2013 Q1 | 58.26 Million EUR | -4.88% |
| 2013 Q3 | 54.07 Million EUR | -5.38% |
| 2013 Q2 | 57.15 Million EUR | -1.91% |
| 2013 Q4 | 52.65 Million EUR | -2.63% |
| 2013 FY | 52.65 Million EUR | -14.04% |
| 2012 Q4 | 61.25 Million EUR | -1.64% |
| 2012 FY | 61.25 Million EUR | 0.0% |
| 2012 Q3 | 62.27 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1588.926% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -6255.415% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -12038.841% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -200.512% |
| GB Sciences, Inc. | 103.44 Thousand USD | -30560.66% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -254.402% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -177282.55% |
| Skye Bioscience, Inc. | 11.94 Million USD | -165.619% |
| Zenith Capital Corp. | 7410.00 USD | -427916.194% |
| Agentix Corp. | 261.39 Thousand USD | -12033.501% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1519.66% |
| Biomind Labs Inc. | 73.81 Thousand USD | -42864.548% |
| ContraFect Corporation | 20.67 Million USD | -53.373% |
| CSL Limited | 38.02 Billion USD | 99.917% |
| CytoDyn Inc. | 11.13 Million USD | -184.806% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4015.519% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -13.498% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -6499.841% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -43727.817% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -8869.026% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 75.643% |
| SQZ Biotechnologies Company | 107.18 Million USD | 70.411% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -857.316% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 18.357% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2114.755% |
| Mesoblast Limited | 667.9 Million USD | 95.251% |
| Marizyme, Inc. | 22.01 Million USD | -44.065% |
| Genus plc | 1.02 Billion USD | 96.917% |
| Pharming Group N.V. | 462.85 Million USD | 93.148% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -4958.373% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -8198.773% |
| IMV Inc. | 31.33 Million USD | -1.22% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -664.974% |
| MultiCell Technologies, Inc. | 126.22 USD | -25127455.063% |
| ONE Bio Corp. | 70.08 Million USD | 54.747% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 75.32% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 9.844% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2089.057% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -5.667% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1054.848% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -4513.33% |
| Alpha Cognition Inc. | 2.45 Million USD | -1193.385% |
| Enzolytics Inc. | 361.7 Million USD | 91.232% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.302% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 33.512% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -4858.29% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.063% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -339.294% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -41438.099% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -9755.627% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -12034.801% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3317.816% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2234.886% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -8024.683% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3275.159% |
| Helix BioMedix, Inc. | 3.02 Million USD | -948.433% |
| EV Biologics, Inc. | 431.71 Thousand USD | -7246.53% |
| Q BioMed Inc. | 3.51 Million USD | -802.172% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 39.819% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 92.894% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -117.825% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1118.349% |
| HST Global, Inc. | 1526.00 USD | -2078274.836% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1372887.013% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3110.229% |
| Halberd Corporation | 10.13 Thousand USD | -312958.928% |
| Resverlogix Corp. | 8.11 Million USD | -290.832% |
| Cell Source, Inc. | 195.17 Thousand USD | -16150.365% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -139121.281% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -329.922% |
| Ember Therapeutics, Inc. | 184.00 USD | -17236856.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -50851.035% |
| Kadimastem Ltd | 2.3 Million USD | -1276.515% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -33055.963% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -55450.496% |
| LadRx Corporation | 2.3 Million USD | -1274.247% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -8869.026% |
| Affymax, Inc. | 7.44 Million USD | -326.119% |
| Itoco Inc. | 1.4 Million USD | -2165.312% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -29820.755% |
| Mobile Lads Corp. | 52.00 USD | -60992207.692% |
| International Stem Cell Corporation | 5.39 Million USD | -488.423% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -22943.055% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -22083.365% |
| Qrons Inc. | 420.00 USD | -7551328.571% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -8127.856% |
| SYBLEU INC | 330.46 Thousand USD | -9497.298% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -5644.403% |
| Rebus Holdings, Inc. | 5000.00 USD | -634220.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -7646.53% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -111.414% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -91.302% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -40046.835% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -3567.959% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -321.924% |
| Neutra Corp. | 2851.00 USD | -1112351.771% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 2.129% |
| PureTech Health plc | 693.97 Million USD | 95.43% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -292.958% |
| IXICO plc | 15.84 Million USD | -100.178% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -282.951% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 69.304% |
| CSL Limited | 38.02 Billion USD | 99.917% |
| Cellectis S.A. | 333.99 Million USD | 90.504% |